Hem/Onc Roundup: FDA Approves New Prostate Cancer Drug, e-Cigarettes and Cancer Risk, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved a new prostate cancer therapy, the World Health Organization (WHO) said electronic cigarettes (e-Cigarettes) and heated tobacco products do not help reduce cancer, and more.

The FDA approved the androgen receptor inhibitor Nubeqa® (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer. In the ARAMIS trial, median metastasis-free survival (primary endpoint) was 40.4 months with darolutamide versus 18.4 months with placebo.

A report from Reuters noted that lymphoma patients are increasingly turning to experimental cancer treatments rather than chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.

A report WHO indicated that e-Cigarettes and heated tobacco products do not help reduce cancer. The seventh WHO report on the global tobacco epidemic also said that these products are “not harmless” and should be considered for regulation as harmful products.

The use of deep natural language processing appears to expedite the curation of relevant cancer outcomes while facilitating rapid learning from electronic health record data, according to a study published in JAMA Oncology.